Antibiograms Guide Targeted Treatment for Hospital‑Acquired Infections

Hospital‑acquired bacteria such as methicillin‑resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, vancomycin‑resistant Enterococcus (VRE) and certain Escherichia coli strains can cause lung, urinary‑tract, surgical‑wound and bloodstream infections. These infections prolong treatment, increase complications, and especially endanger immunocompromised, elderly, neonatal, oncology and intensive‑care patients, as well as those with catheters or mechanical ventilation.

When a bacterial isolate is obtained, an antibiogram tests its susceptibility to a range of antibiotics. The result identifies which drugs the organism is sensitive to and which it resists, allowing clinicians to choose the most appropriate therapy promptly. Early, targeted treatment shortens hospital stays, reduces mortality risk, and helps limit the unnecessary use of broad‑spectrum antibiotics, which drives the global rise of antimicrobial resistance.

The spread of resistant bacteria underscores the need for strict infection‑control measures and judicious antibiotic prescribing in all health‑care settings.